The Animal Imaging Core provides services for molecular imaging of rodent models of human cancer.The Core provides investigators with non-invasive, high-resolution quantitative imaging-based capabilitiesfor metabolic and genetic characterization of tumors and their microenvironment, including in vivo traffickingof tumor cells. This is accomplished by monitoring of 'directly-targeting' probes and of the expression ofsingle and multi-modality reporter genes using optical (bioluminescence and fluorescence), radionuclide(PET, SPECT, and autoradiography), MRI/MRS, CT, and US imaging. These imaging techniques are wellestablishedat MSKCC for small-animal imaging studies. They are quantitative and non-invasive and thusreadily adaptable to longitudinal studies. The Animal Imaging Core also provides investigators with accessto critical ancillary equipment and services such as a Fuji Film BAS-180011 phosphor-plate digitalautoradiography system, a digital-camera-equipped Olympus B 201 fluorescence microscope withmotorized stage, and a Microm HM500M cryostatic microtome.As part of a major expansion and modernization of MSKCC's infrastructure (Phase 1), part of the ImagingCore has recently re-located to the C4 level within the Vivarium of the new Zuckerman Research Center.This area provides enhanced biosecurity and functionality and houses our R4 and Focus 120 microPETdedicated high-resolution small-animal (rodent) PETs, new MS 200 optical imaging system, microCAT IIdedicated small-animal (rodent) CT, and X-SPECT dedicated small-animal SPECT-CT. The existing MS100 optical imaging system and recently installed Vevo 770 ultrasound system have been re-located torefurbished space on the 12th floor of the Rockefeller Research Laboratory providing improved access tothe primary users of these two systems. The Imaging Core's 4.7-T 40-cm bore and 7.0-T 31-cm BruckerNMR imaging and spectroscopy systems are currently located in the MRI Building. In Phase 2 of MSKCC'scapital expansion and modernization, all of the foregoing instrumentation of the Imaging Core will beconsolidated in spacious, state-of the-art quarters with the Center's vivarium.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-43
Application #
7671810
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-07-31
Project End
2012-12-31
Budget Start
2008-07-31
Budget End
2008-12-31
Support Year
43
Fiscal Year
2008
Total Cost
$136,415
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Ho, A L (2018) Developing androgen receptor targeting for salivary gland cancers. Ann Oncol 29:792-794
Gupta, Piyush; Migliacci, Jocelyn C; Hay, Ashley et al. (2018) Validation and assessment of discordance of the 8th edition AJCC (American Joint Committee on Cancer) clinical and pathologic staging systems in patients with p16+ oropharyngeal cancer treated with surgery and adjuvant radiation at a single institution. Oral Oncol 83:140-146
Aras, Omer; Pearce, Gillian; Watkins, Adam J et al. (2018) An in-vivo pilot study into the effects of FDG-mNP in cancer in mice. PLoS One 13:e0202482
Chou, Chun; Li, Ming O (2018) Tissue-Resident Lymphocytes Across Innate and Adaptive Lineages. Front Immunol 9:2104
Quezada-Diaz, Felipe; Jimenez-Rodriguez, Rosa M; Pappou, Emmanouil P et al. (2018) Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal Excision. J Gastrointest Surg :
Schleicher, Stephen M; Bach, Peter B; Matsoukas, Konstantina et al. (2018) Medication overuse in oncology: current trends and future implications for patients and society. Lancet Oncol 19:e200-e208
Moore, Amanda R; Ran, Leili; Guan, Youxin et al. (2018) GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Rep 22:2455-2468
Davis, Mellar P; Pasternak, Gavril; Behm, Bertrand (2018) Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option. Drugs 78:1211-1228
Suzawa, Ken; Offin, Michael; Lu, Daniel et al. (2018) Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clin Cancer Res :
Horvat, Joao V; Durando, Manuela; Milans, Soledad et al. (2018) Apparent diffusion coefficient mapping using diffusion-weighted MRI: impact of background parenchymal enhancement, amount of fibroglandular tissue and menopausal status on breast cancer diagnosis. Eur Radiol 28:2516-2524

Showing the most recent 10 out of 8799 publications